ArticleMolecular cancer therapeutics2016

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.

Natalie A Jabbour-Leung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.